Effects of low-dose bortezomib plus thalidomide and chemotherapy in treatment of multiple myeloma
10.3760/cma.j.issn.1009-9921.2011.01.010
- VernacularTitle:低剂量硼替佐米联合沙利度胺及化疗治疗多发性骨髓瘤35例
- Author:
Mei XIONG
;
Zhao WANG
;
Na WEI
;
Lingzhi YANG
;
Li FU
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Drug therapy,combination
- From:
Journal of Leukemia & Lymphoma
2011;20(1):29-31,48
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the curative effects and toxicity of low-dose bortezomib plus thalidomide and chemotherapy in treatment of multiple myeloma. Methods 35 patients with initial, refractory or relapsed MM received at least two cycles of treatment with bortezomib at 1.1 mg/m2 intravenously on days 0,3, 7, and 10, and by daily oral thalidomide escalated from 50mg to 150 mg and chemotherapy. The chemotherapy regimens included MP, VAD and AD regimen which was chosen according to the status of patients. Results After a median follow-up of 20 months, the overall response rate was 82.8 %, complete remission (CR)48.6 %, very good partial remission (VEPR) 17.1%, and partial remission 17.1%. The 3-year PFS and OS were 60.92 % and 72.41% separately. ORR and OS were same in initial and refractory or relapsed MM patients. Grade 3 or 4 adverse events including debility (3/35), nausing and vomiting (8/35), constipation (4/35), peripheral sensory neuropathy (3/35), neutropenia (10/35) and thrombocytopenia (12 %) were observed.Conclusion The regimen of low-dose bortezomib plus thalidomide and chemotherapy is a highly effective and safety regimen for MM patients. The maintenane therapy with thalidomide may prolong PFS.
